Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events (AEs) are still scarce. Methods. We conducted a retrospective cohort study including all patients who were prescr...

Descripció completa

Dades bibliogràfiques

Autors principals:	Maria Mazzitelli, Daniele Mengato, Lolita Sasset, Anna Ferrari, Samuele Gardin, Vincenzo Scaglione, Nicola Bonadiman, Lucrezia Calandrino, Silvia Cavinato, Sabrina Trivellato, Francesca Venturini, Anna Maria Cattelan
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2023-01-01
Col·lecció:	Viruses
Matèries:	molnupiravir nirmatrelvir/ritonavir tolerability adverse drug reaction adherence COVID-19
Accés en línia:	https://www.mdpi.com/1999-4915/15/2/384
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!